1-3 of 3
S. O’Brien, MD
Close
Sort by
Journal Articles

Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, S. Faderl, MD, A. Ferrajoli, MD, G. Garcia-Manero, MD, J. Burger, MD, E. Schlette, MD, L. Abruzzo, MD, PhD, S. Lerner, MS, BA, M. Keating, MB, BS
Journal: Blood
Blood (2007) 110 (11): 2065.
https://doi.org/10.1182/blood.V110.11.2065.2065
Published: 2007
Journal Articles

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

William G. Wierda, MD, PhD, S. O’Brien, MD, A. Ferrajoli, MD, S. Faderl, MD, C. Koller, MD, Z. Estrov, MD, G. Garcia-Manero, MD, S. Verstovsek, MD, M. Browning, BSN, ADN, S. Lerner, MS, BA, M. Keating, MB, BS
Journal: Blood
Blood (2007) 110 (11): 628.
https://doi.org/10.1182/blood.V110.11.628.628
Published: 2007
Journal Articles

A Phase I/II Study of AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, on a Continuous Daily Dosing Schedule in Adult Patients (pts) with Imatinib-Resistant Advanced Phase Chronic Myeloid Leukemia (CML) or Relapsed/Refractory Philadelphia Chromosome (Ph+) Acute Llymphocytic Leukemia (ALL).

Francis Giles, MD, H. Kantarjian, MD, B. Wassmann, J. Cortes, MD, S. O’Brien, MD, C. Tanaka, P. Rae, W. Mietlowski, A. Romano, L. Alland, M. Dugan, M. Albitar, MD, O. Ottmann
Journal: Blood
Blood (2004) 104 (11): 22.
https://doi.org/10.1182/blood.V104.11.22.22
Published: 2004